NCT02497131View on ClinicalTrials.gov

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 21, 2015

Primary Completion Date

September 24, 2019

Study Completion Date

March 31, 2022

Conditions

Lymphatic Diseases

Interventions

DRUG

Brentuximab Vedotin

Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes

Trial Locations (4)

10126

SC Ematologia - Città della Salute e della Scienza, Torino

33100

A.O. Universitaria S. Maria Della Misericordia Di Udine, Udine

40138

"Ematologia L. & A. Seragnoli - Policlinico S. Orsola Malpighi", Bologna

Unknown

Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori, Milan

All Listed Sponsors

lead

Fondazione Italiana Linfomi - ETS

OTHER

NCT02497131 - Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients | Biotech Hunter | Biotech Hunter